The type 2 diabetes segment dominated the market with a 55% share in 2025 because GLP-1 therapies have been used for glycemic control for a long time, and diabetes is very common worldwide
Dulaglutide, developed by Eli Lilly, is a once-weekly GLP-1 RA like albiglutide, but with some key differences
Disclaimer: Information and statements regarding the product/services have not been evaluated by the Food and Drug Administration or any government authority and not intended to diagnose, treat, cure, or prevent any disease_ Product/Services reviews are provided by users based on their persona, experiences & opinions, and do not reflect the opinion of HealthKart_ Product/Services information provided by the seller on HealthKart is not exhaustive, please read the label on the product carefully for complete information provided by the manufacturer_ The results from the products will vary from person to person_ No individual result should be seen as typical_
Beauverd et al
Human dosing strategies are still being refined
[11] Electrolytes: Checks sodium, potassium, and others
